Minakem Header W48

Minakem Header W48

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Horizon Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA® (teprotumumab-trbw) Comparable with Clinical Trial Observations

Details:

Tepezza, (teprotumumab-trbw) first medicine approved by FDA for treatment of TED, among thousands of patients included in this 19-month new post-marketing Safety analysis, approximately 10% of all cases reported to safety database have included a hearing-related event.

Lead Product(s): Teprotumumab

Therapeutic Area: Immunology Product Name: Tepezza

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 15, 2022

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY